Our Team
Nabil Gharios
Founder
Nabil Gharios started his career in 1999 at SG Cowen, as a financial analyst for the healthcare M&A division in New York. Between 2001 and 2005, Nabil was an associate at Bioam, a €51m venture-capital fund specialized in biotechnologies based in Paris. He then worked for 5 years at Abbott Laboratories where he held several positions, including manager of the European business development team, international brand manager for anesthesia (600 M€ revenue) and special project manager for the European Headquarter. In late 2011, Nabil founded Biotech Promise, a specialized investment fund dedicated to listed biotech and medtech companies. He still serves as Chairman of Healthcare Promise Investment Partners, the General Partner of this fund.
​
Nabil graduated from Ecole Centrale de Paris, a leading French engineering university, and is currently responsible for the healthcare sector of the French Society of Financial Analysts (SFAF).
Claire joined DNA Finance in 2021 to work on strategy and fund-raising assignments encompassing new product planning and go-to-market strategy for biotech, medtech and diagnostic companies.
Prior to joining DNA Finance, Claire worked as an analyst at TechLife Capital, a Growth Equity fund, where she participated in due-diligences and investments in healthcare and tech companies, and in the portfolio monitoring.
​
Claire graduated from AgroParisTech, France’s leading engineering school in human health and bioproducts where she specialized in Finance and Business Management. She also holds a certification in Sustainable Finance (CARE, CERCES certification).
Claire Bendao
Associate
Philippe Berthon,PhD
Partner
Philippe is CEO of BlueBees Therapeutics, a biotech developing new immunotherapies in oncology.
Philippe has held several leadership positions as CEO in biotech and medtech. Philippe was CEO of Culture Top (sold to Eurofins in 2021), Tridek One, Aurgalys (sold to Genesta/In extenso in 2018), Vaxon-Biotech and UroGene (sold to Pierre Fabre in 2004). Also he co-founded and led, up to 1999, the Research Urology Dept at Hospital St Louis in Paris. As such, he has an extensive background in strategic planning, financing, operations, business development & R&D with > 50 international scientific publications.
Philippe holds a PhD in Reproduction Physiology, Sorbonne Univ. (PM Curie) and a business management diploma from HEC.
Marie-Helene Leopold
Partner
Marie-Hélène Leopold began her career in 1985 at BNP as a Pharma Monde analyst. From 1987 to 1994, she was a Sell-Side Pharma Europe analyst at NatWest Securities, then between 1994 and 2000, she headed the teams of Pharma and Biotech Europe analysts at BNPParibas. In 2000, she became a Partner at Global Private Equity, in charge of raising funds for European private Biotech and MedTech companies. From 2003 to 2007, she led SG Cowen's team of Sell-Side Pharma, Biotech and MedTech analysts. From 2007 to 2018, she was a Buy-Side analyst in charge of the Pharma and MedTech/Healthcare sector at Amundi Asset Management.
​
Marie-Hélène holds a postgraduate degree in Cellular and Molecular Biology and a postgraduate degree in Corporate Finance from Pierre and Marie Curie University. She also obtained a certificate from Johns Hopkins University (USA) on Cancer Biology. From 1987 to 2007, she was head of the Health Sector of the French Society of Financial Analysts (SFAF). She was elected best Pharma Europe analyst in the Extel ranking (2015, 2017) and systematically in the Top 3 between 2008 and 2018. Marie-Hélène is also a certified HEC Executive Coach.
Pascale Altier
Partner
Pascale is an innovation consultant in the life sciences through the biotech, medtech and e-health ecosystem. Pascale is a member of the scientific committee and of the ethics committee of the National Cancer Institute (INCa), a member of the ethics committee of the Fédération Hospitalière de France (FHF). Previously, she was successively general manager of biotech incubators at the Institut Pasteur, then of Ipeps-ICM at the Pitié-Salpêtrière hospital in Paris. Before, she was project manager at Genopole, at BioCrit in Paris Ile-de-France, and worked as a marketing manager for the medtech company Inoteb.
​
Pascal is a graduate in biology from the University of Paris-Est Créteil.
Sonia Escaich,PhD
Partner
Sonia is CEO of V4Cure, a biotech developing drugs derived from potent molecules found in animal venoms. Previously she was COO of 4P-Pharma and Regulaxis, two biotech where she coordinated the R&D operations. Dr. Escaich co-founded and headed for 8 years Mutabilis, a company developing therapeutic molecules for the treatment of bacterial infections. She has also held leadership roles at Sandoz, Sytemix, Sanofi Aventis, Fabpharma and Biosantech.
Sonia holds a PhD in microbiology with a specialization in Virology, and a post doctorate in Sandoz in Vienna.
Caryn Trocme-Thibierge
Partner
Caryn is currently an advisor for biotech in their fund-raising and Business Development.
She has over 25 years’ experience in pharma/biotech R&D and Business Development/M&A. She concluded numerous deals (in/out-licensing, R&D collaborations, M&A) on a wide range of modalities (small molecules, gene therapies …) and stages (research to post MA).
Caryn started her carrier as a researcher at CNRS, spent 20 years at Servier in R&D and BD positions, 4 years at UCB as BD Transactions Director and then joined Gensight Biologics as VP Business Development.
​
Caryn holds a PhD in molecular biology, an AgroParisTech Engineer diploma and a Finance certificate from HEC
Pamela Graves Moore
Partner
Pamela is a strategic advisor at Vault Fund, a fund of funds. She is also Principal at Patient Input Advisory, an advisory firm providing services to patient groups and Pharmas.
Pamela launched her U.S. and Global Government Relations career with Searle/Pharmacia. Then, she relocated to Europe as Aventis' Head of EU Public Affairs and then as Abbott's Head of European Government Affairs. She conceived and led Global Strategic Health Initiatives at AbbVie, and Global Public Affairs & Patient Advocacy at Sanofi Genzyme Rare Diseases.
​
Pamela graduated from Miami University, The Chicago Management Institute and the University of Chicago Booth School of Business.